[go: up one dir, main page]

WO2006071024A1 - Préparation comprenant un extrait de rubus coreanus miquel au titre de principe actif et stimulant la sécrétion de testostérone - Google Patents

Préparation comprenant un extrait de rubus coreanus miquel au titre de principe actif et stimulant la sécrétion de testostérone Download PDF

Info

Publication number
WO2006071024A1
WO2006071024A1 PCT/KR2005/004456 KR2005004456W WO2006071024A1 WO 2006071024 A1 WO2006071024 A1 WO 2006071024A1 KR 2005004456 W KR2005004456 W KR 2005004456W WO 2006071024 A1 WO2006071024 A1 WO 2006071024A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
group
testosterone
inventive
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2005/004456
Other languages
English (en)
Inventor
Jae Heuk Kim
Pill Jae Park
Byeong Kirl Baek
Hee Kwon Lee
Chae Woong Lim
Byung Hun Jeon
Ki Dong Jin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JEOLLABUK-DO GOCHANG-GUN
Original Assignee
JEOLLABUK-DO GOCHANG-GUN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JEOLLABUK-DO GOCHANG-GUN filed Critical JEOLLABUK-DO GOCHANG-GUN
Publication of WO2006071024A1 publication Critical patent/WO2006071024A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to a composition
  • a composition comprising an extract of Rubus coreanus Miquelas an active ingredient showing potent stimulating effect on testosterone excretion.
  • Erectile dysfunction or sexual impotence is caused by psychological disorder, physiological disorder or the combination thereof.
  • Organic erectile dysfunction, a main reason of erectile dysfunction is caused by various factors such as blood vessel disorder, neurologic deficiencies and the adverse action by drug treatment.
  • the primary cause of erectile dysfunction is arterial incompetence which blocks the blood filling in penis and another is venous abnormality which blocks the maintenance of blood filling during erection.
  • the arterial incompetence is caused by arteriosclerosis, which has been found to become worse by smoking.
  • the inventors of the present invention have intensively carried out animal model experiments using by Sprague-dawley rat and rabbit treated with antaphrodisiac drug and determined various factors, i.e., the change of body, liver, testis, the amount of testosterone and estrogen, sperm mobility, liver function, together with microscopic observation of Leydig cell or spermatocyte in testis etc., and finally completed present invention by confirming that the extract enhance and potentiate sexual function.
  • the present invention provides a pharmaceutical composition comprising an extract of Rubus coreanus Miquel, as an active ingredient in an effective amount to treat and prevent sexual dysfunction caused by testosterone decrease.
  • the present invention also provides a use of above extract for the manufacture of pharmaceutical composition to treat and prevent sexual dysfunction caused by testosterone decrease in mammal or human.
  • the present invention also provides a health food or food additive comprising above extract for the prevention or alleviation of sexual dysfunction caused by testosterone decrease.
  • an extract means polar solvent soluble extract of Rubus coreanus Miquel, which can be prepared by the steps consisting of: extracting the fruit, root, or herb of plant material with polar solvent such as water, lower alcohols such as methanol, ethanol, preferably ethanol and the like or the mixtures thereof.
  • a fermented extract means fermented extract of Rubus coreanus Miquel, which can be prepared by the steps consisting of: fermenting the polar solvent soluble extract of Rubus coreanus Miquel, with one yeast or the combination thereof selected from Saccharomyces cerevisiae, red wine dry yeast and natural yeast in Rubus coreanus Miquel.
  • the inventive polar solvent soluble extract can be prepared by follows; fruit, root, or herb of plant material is dried, cut, crushed and mixed with 5 to 25-fold, preferably, approximately 10 fold volume of distilled water, lower alcohols such as methanol, ethanol, butanol and the like or the mixtures thereof, preferably water or ethanol; the solution is treated with hot water at the temperature ranging from 20 to 100°C, preferably from 50 to 100°C, for the period ranging from 0.5 to 6 hours, preferably from 1 to 3 hours with extraction method by the extraction with hot water, cold water, reflux extraction or ultra-sonication extraction, preferably hot water extraction with 1 to 12 times, preferably 2 to 3 times, consecutively; the residue is filtered to obtain the supernatant to be concentrated with rotary evaporator, at the temperature ranging from 20 to 100°C, preferably from 40 to 70 °C and then dried by vacuum freeze-drying, hot air-drying or spray drying to obtain dried crude extract powder which can be soluble in water, lower alcohols
  • the inventive fermented extract can be prepared by following steps; the water extract ofRubus coreanus Miquel prepared by the procedure disclosed in the above described step to obtain polar solvent soluble extract is filtrated at 1 st step; the filtrated water extract is subjected to be sterilized, cooled and enriched with yeast at 2 nd step; the enriched medium is loaded to obtain mashed ferment at 3 step; the mashed ferment and sulfurous acid are added to crushed strawberry fruit supplemented with sucrose and subjected to main fermentation under aerobic condition to produce precipitates at 4 th step; the remaining precipitates is removed at 5 th step to obtain fermented extract o ⁇ Rubus coreanus Miquel of the present invention.
  • the inventive fermented extract can be prepared by follow, which intends to explain present invention not to limit the scope of the invention;
  • the water extract o ⁇ Rubus coreanus Miquel prepared by the procedure disclosed in above described step is filtrated and dissolved in distilled water to dilute at 1 st step;
  • the filtrated water extract is subjected to be sterilized, cooled, and subjected to fermentation with appropriate amount of yeast selected from Saccharomyces cerevisiae, red wine dry yeast and natural yeast in Rubus coreanus Miquel, preferably, KCCM 24, 42, 54, 48, 50, 27, 30, 34, 37 strain or the combination thereof in the temperature ranging from 20 to 40°C, preferably 30°C in the period ranging from 10 to 48 hours, preferably, 18 to 22 hours at 2 n step;
  • the water extract, sulfurous acid and enriched medium are added thereto to subject to fermentation in the temperature ranging from 12 to 36 hours, preferably, 24 hours to obtain mashed ferment at 3 rd step;
  • composition of the present invention can contain about 0.01 ⁇
  • the health food of the present invention comprises as 0.01 to 80 %, preferably 1 to
  • Above health food can be contained in health food, health beverage etc, and may be used as powder, granule, tablet, chewing tablet, capsule, beverage etc.
  • water extract o ⁇ Rubus coreanus Miquel and the fermented extract thereof prepared by the procedure disclosed in above described step on testosterone secretion through animal model experiments using by Sprague-dawley rat and rabbit treated with antaphrodisiac drug and determined various factors, i.
  • the inventive extract significantly increase the amount of testosterone and the distribution of Leydig cells producing testosterone therefore it could be useful as a drug and health care food to treating or prevent sexual dysfunction caused by testosterone decrease .
  • the inventive extract can be used for a ling term with safe and no toxicity.
  • a pharmaceutical composition comprising the polar solvent soluble extract o ⁇ Rubus coreanus Miquel prepared by the above preparation method for the treatment and prevention of sexual dysfunction caused by testosterone decrease.
  • the inventive composition for treating and preventing sexual dysfunction caused by testosterone decrease may comprises 0.01 ⁇ 50 % the above extract by weight based on the total weight of the composition.
  • the inventive composition may additionally comprise conventional carrier, adjuvants or diluents in accordance with a using method well known in the art. It is preferable that said carrier is used as appropriate substance according to the usage and application method, but it is not limited. Appropriate diluents are listed in the written text of Remington's Pharmaceutical Science (Mack Publishing Co, Easton PA).
  • composition according to the present invention can be provided as a pharmaceutical composition containing pharmaceutically acceptable carriers, adjuvants or diluents, e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl pyrrolidone, water, methylhydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate and mineral oil.
  • pharmaceutically acceptable carriers e.g., lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starches, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, polyvinyl
  • the formulations may additionally include fillers, anti-agglutinating agents, lubricating agents, wetting agents, flavoring agents, emulsifiers, preservatives and the like.
  • the compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after their administration to a patient by employing any of the procedures well known in the art.
  • compositions of the present invention can be dissolved in oils, propylene glycol or other solvents that are commonly used to produce an injection.
  • suitable examples of the carriers include physiological saline, polyethylene glycol, ethanol, vegetable oils, isopropyl myristate, etc., but are not limited to them.
  • the extract of the present invention can be formulated in the form of ointments and creams.
  • compositions containing present composition may be prepared in any form, such as oral dosage form (powder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule), or topical preparation (cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like), or injectable preparation (solution, suspension, emulsion).
  • oral dosage form prowder, tablet, capsule, soft capsule, aqueous medicine, syrup, elixirs pill, powder, sachet, granule
  • topical preparation cream, ointment, lotion, gel, balm, patch, paste, spray solution, aerosol and the like
  • injectable preparation solution, suspension, emulsion
  • composition of the present invention in pharmaceutical dosage forms may be used in the form of their pharmaceutically acceptable salts, and also may be used alone or in appropriate association, as well as in combination with other pharmaceutically active compounds.
  • the desirable dose of the inventive extract or composition varies depending on the condition and the weight of the subject, severity, drug form, route and period of administration, and may be chosen by those skilled in the art. However, in order to obtain desirable effects, it is generally recommended to administer at the amount ranging 10 g/kg, preferably, 1 to 3 g/kg by weight/day of the inventive extract or compounds of the present invention. The dose may be administered in single or divided into several times per day. In terms of composition, the amount of inventive extract should be present between 0.01 to 50% by weight, preferably 0.5 to 40% by weight based on the total weight of the composition.
  • composition of present invention can be administered to a subject animal such as mammals (rat, mouse, domestic animals or human) via various routes. All modes of administration are contemplated, for example, administration can be made orally, rectally or by intravenous, intramuscular, subcutaneous, intracutaneous, intrathecal, epidural or intracerebroventricular injection.
  • the present invention provide a composition of the health food beverage added with above described extract 0.01 to 80 % by weight, amino acids 0.001 to 5 % by weight, vitamins 0.001 to 2 % by weight, sugars 0.001 to 20 % by weight, organic acids 0.001 to 10 % by weight, sweetener and flavors of proper amount.
  • inventive extract can be added to food and beverage for the prevention and improvement of sexual dysfunction caused by testosterone decrease.
  • examples of addable food comprising the above extract of the present invention are various food, beverage, gum, vitamin complex, health improving food and the like, and can be used as powder, granule, tablet, chewing tablet, capsule or beverage etc.
  • the extract of the present invention will be able to prevent and improve sexual dysfunction caused by testosterone decrease by way of adding to child and infant food, such as the form of modified milk powder, modified milk powder for growth period, modified food for growth period.
  • composition therein can be added to food, additive or beverage, wherein the amount of above described extract in food or beverage may generally range from about 0.1 to 80w/w %, preferably 1 to 50 w/w % of total weight of food for the health food composition and 1 to 30 g, preferably 3 to 10 g on the ratio of 100 ml of the health beverage composition.
  • the health beverage composition of present invention contains above described extract as an essential component in the indicated ratio
  • the other component can be various deodorant or natural carbohydrate etc such as conventional beverage.
  • natural carbohydrate are monosaccharide such as glucose, fructose etc; disaccharide such as maltose, sucrose etc; conventional sugar such as dextrin, cy- clodextrin; and sugar alcohol such as xylitol, and erythritol etc.
  • natural deodorant such as taumatin, stevia extract such as levaudioside A, glycyrrhizin et al., and synthetic deodorant such as saccharin, aspartam et al.
  • the amount of above described natural carbohydrate is generally ranging from about 1 to 20 g, preferably 5 to 12 g in the ratio of 100ml of the present beverage composition.
  • the other components than aforementioned composition are various nutrients, a vitamin, a mineral or an electrolyte, synthetic flavoring agent, a coloring agent and improving agent in case of cheese chocolate et al., pectic acid and the salt thereof, alginic acid and the salt thereof, organic acid, protective colloidal adhesive, pH controlling agent, stabilizer, a preservative, glycerin, alcohol, carbonizing agent used in carbonate beverage et al.
  • the other component than aforementioned ones may be fruit juice for preparing natural fruit juice, fruit juice beverage and vegetable beverage, wherein the component can be used independently or in combination.
  • the ratio of the components is not so important but is generally ranging from about 0 to 20 w/w % per 100 w/w % the present composition.
  • Examples of addable food comprising aforementioned extract therein are various food, beverage, gum, vitamin complex, health care food and the like.
  • the inventive composition may additionally comprise one or more than one of organic acid, such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid; phosphate, such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate; natural anti-oxidants, such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • organic acid such as citric acid, fumaric acid, adipic acid, lactic acid, malic acid
  • phosphate such as phosphate, sodium phosphate, potassium phosphate, acid pyrophosphate, polyphosphate
  • natural anti-oxidants such as polyphenol, catechin, ⁇ - tocopherol, rosemary extract, vitamin C, green tea extract, licorice root extract, chitosan, tannic acid, phytic acid etc.
  • the amount of above-described inventive extract may be 20 to 90 % in high concentrated liquid, power or granule type.
  • the above-described extract of the present composition can comprise additionally one or more than one of lactose, casein, dextrose, glucose, sucrose and sorbitol.
  • the inventive extract significantly increases the amount of testosterone and the distribution of Leydig cells producing testosterone with no toxicity therefore it could be useful as a drug and health care food to treat or prevent sexual dysfunction caused by testosterone decrease.
  • Fig. 2 shows the change of testosterone level in Group A treated with MET for 1 week and inventive extract of the present invention, Group B treated with only MET and Group C treated with only inventive fermented extract; [98] [99] Fig. 3 represents the change of estrogen level in Group A treated with MET for 1 week and inventive extract of the present invention, Group B treated with only MET and Group C treated with only inventive fermented extract; [100] [101] Fig. 4 represents the sperm motility in Group C treated with only inventive fermented extract; [102]
  • Fig. 5 presents the sperm motility in Group B treated with only MET
  • Fig 6 depicts the distribution of the Leydig cell or spermatocyte cell of rat in Group treated with MET for 1 week and inventive extract of the present invention
  • Fig 7 depicts the distribution of the Leydig cell or spermatocyte cell of rat in Group treated with MET for 1 week and following inventive extract for 5 weeks
  • Fig 8 shows the distribution of the Leydig cell or spermatocyte cell of rat in Group treated with only MET for 1 week;
  • Fig 9 shows the distribution of the Ley dig cell or spermatocyte cell of rabbit in
  • Fig 10 represents the distribution of the Leydig cell or spermatocyte cell of rat in
  • Experiment Station location: San 13 Yongsan-ri, Buan-myeon, Gochang-Gun, Jeonbuk, 585-943, Korea
  • the extract was kept before use in freeze drying room maintaining the temperature at -20°C and used by filtrating with filter paper (diameter 150 mm).
  • Experiment Station location: San 13 Yongsan-ri, Buan-myeon, Gochang-Gun, Jeonbuk, 585-943, Korea
  • 10 kg of ethanol was added thereto and the solution was subjected to reflux extraction two times for 2 hours at 80°C.
  • the extract was centrifuged and the polled supernatant was concentrated in vaccuo with rotary vaccum evaporator at 60°C.
  • Resulting concentrate was dried with freezing dryer (Speed Spec 3000, Bio-Rad Co. U.S.A.) to obtain alcohol soluble extract.
  • Example 1-1 1125 ml of water extract prepared in Example 1-1 was poured in 2000 ml of Erlenmeyer flask. Appropriate amount of sulfurous acid was added thereto to the extent that the final concentration is reached to 100-200 ppm and 125 ml of enriched medium are added thereto to subject to fermentation for 24 hours to obtain mashed ferment.
  • Example 1 on erectile dysfunction syndrome following experiment was performed.
  • Methoxychlor (MET, M1501, Sigma Co.), an antaphrodisiac drug, was administrated into the test animals for 1 week in an amount of 100mg/kg per day.
  • the test animals were divided into six groups, i.e., a group treated with inventive extract and MET every day (Group A), a group treated with only MET (Group B), a group treated with inventive fermented extract (Group C), a group treated with only Sac- chromyces cerevisiae medium (Group D), a group treated with fruit water extract of Rubus coreanus Miquel (Group E), a group treated with only 13% alcohol (Group F), in accordance with the schedule disclosed in Table 1.
  • Table 1 The change of blood component and blood sexual hormone, and the morphology of testicular tissue using optical microscopy were examined.
  • Table 1 The treatment schedule for respective group (rats)
  • Methoxychlor (MET, M1501, Sigma Co.), an antaphrodisiac drug, was administrated into the test animalsby the procedure disclosed in the literature (Latchoumycandane C, et al., Reproductive Toxicology 16, ppl61-172. 2002).
  • test animals Prior to administration, all the test animals were starved from p.m. 5:00 to a.m.
  • test samples i.e.,inventive fermented extract prepared in Example 1-3, inventive water extract prepared in Example 1-1, Sac- chromyces cerevisiae medium, 13% alcohol etc were allowed to freely access to test samples for 1 hour.
  • the total uptake amount of fermented extract in rata and rabbits were 3 ml and 58 ml respectively and that of water extract in eats was 7.7 ml.
  • inventive fermented extract Sacchromyces cerevisiae strain stored in Korean Raspberry Experiment Station was diluted with artificial medium prepared by mixing 6.7g of yeast nitrogen base (Difco USA) and 5g of dextrose with 1000ml of distilled water. The medium was incubated for 72 hours at 25°C, stored in refrigerator before use.
  • Methoxychlor (MET, M1501, Sigma Co.), an antaphrodisiac drug, was administrated into the test animals for 1 week in an amount of 100mg/kg per day.
  • the test animals were divided into six groups, i.e., a group treated with inventive extract and MET every day (Group A), a group treated with only 200mg/kg of MET (Group B), a group treated with inventive fermented extract (Group C), a group treated with only Sacchromyces cerevisiae medium (Group D), a group treated with water extract o ⁇ Rubus coreanus Miquel (Group E), a group treated with only 13% alcohol (Group F) in accordance with the schedule disclosed in Table 1.
  • Group E treated with only inventive water extract and Group F treated with only 13% alcohol was 294.16+12.05g, 312.2+17.36 g, and 341.3+17.36 g respectively at the 5 th week after the administration while the body weight of Group D, Group E and Group F was 287.8+10.4 g, 302.7+13.9 g, and 328.3+5.32 g respectively before the administration as can be seen in following Table 3.
  • Methoxychlor (MET, M1501, Sigma Co.), an antaphrodisiac drug, was orally administrated into the test animals for 1 week in an amount of 200mg/kg per day.
  • the test animals were divided into four groups, i.e., a group treated with inventive fermented extract and MET every day (Group R-A), a group treated with only inventive fermented extract (Group R-B), a group treated with only 13% alcohol (Group R-C) and a group treated with only MET (Group R-D) in accordance with the schedule disclosed in Table 2.
  • the isolated blood serum was reacted with the plated attached with I-isotope labeled antibody against testosterone (DPC, USA) for 3 hours at 37 °C and the radioactivity was determined by Isotope Determining Apparatus according to the Coat- A-Count method at Neodin Co. Ltd in Korea (www.vetlab.co.kr).
  • the amount of testosterone in Group A showed 0.345+0.14g at 1 st week and increased to about 15.1 fold, i.e., 5.18+0.763 ng/ml at 4 th week.
  • the amount of testosterone in Group B showed 0.69+0.183g at 1 st week and decreased to 0.28+0.056 ng/ml at 3 week.
  • the amount of testosterone in Group C showed 0.39+4.2Og at 3 rd week and increased to 7.486+6.482 ng/ml at 5 th week.
  • the blood serum was collected from two rabbits treated with MET and the amount of testosterone in the serum was determined before and after the MET treatment.
  • Inventive fermented extract and 13% alcohol were orally administrated into the animals and the blood testosterone level was determined at every week.
  • the amount of testosterone in Group R-A showed 1.335+1.02 ng/ml at 1 st week and 1.855+2.42 ng/ml at 6 th week after the treatment of inventive fermented extract whereas it showed 1.22+0.810 ng/ml and 0.065+0.02 ng/ ml before and after the MET treatment respectively.
  • the amount of testosterone in Group R-D showed 1.24+0.51 ng/ml before MET th treatment, 0.075+0.22 ng/ml 1 st week after MET treatment and 0.621+0.71 ng/ml at 6 1 week.
  • the amount of testosterone in Group R-B showed 1.25+1.59 ng/ ml before treatment, 2.925+2.62 ng/ml and 2.34+0.07 ng/ml at 1 st and 6 th week after the treatment respectively.
  • the amount of testosterone in Group R-C showed 1.06+0.41 ng/ml before the alcohol treatment and there did not showed significant change in the amount of testosterone.
  • the slices dipped into sperm diluting solution containing 119 mM NaCl, 5mM KCl, 1.2 mM MgSO4, 1OmM Glucose, 16.3 mM Potassium phosphate and 50 units/m; penicillin (pH 6.9) was added to 2ml of comical tube and colleted sperm was placed onto slide glass heated at 37°C. The sperm motility was determined by observing wit microscopic method at every 1 minute.
  • sperm in the diluting solution 5 microliter of the solution was mixed with staining solution prepared by dissolving 50g of sodium bicarbonate, 10 ml of 35% formalin, 0.25 ml trypan blue in 1 liter of distilled water and the determination was performed by Neubauer type hemocytometer at three times.
  • the rabbit testis was delivered, fixed in 10% formalin solution, sliced into slices with the width of 5-6 micrometer, stained with Hematoxylin-eosin dye and observed by microscope.
  • ALT Alanine aminotransferase
  • the level of AST and ALT in Group B showed similar phenomena to that in Group A and those in Group C showed 235.5+4.94 IU/liter and 53+1.41 IU/liter respectively at 1 st week, 235.3+46.60 IU/liter and 70.0+5.29 IU/liter respectively at 5 th week after the treatment.
  • the level of AST and ALT in Group R-A showed 48+15.55 IU/liter and 33.5+16.26 IU/liter respectively at 1 st week.
  • the level of AST showed 56.5+13.43 IU/liter at 2 nd week and that of ALT showed 87.5+57.27 IU/liter respectively at 3 rd week after the treatment.
  • the level of AST and ALT in Group R-B and Group R-C did not show significant difference between before and after the treatment.
  • Powder preparation was prepared by mixing above components and filling sealed package.
  • Tablet preparation was prepared by mixing above components and entabletting.
  • Tablet preparation was prepared by mixing above components and filling gelatin capsule by conventional gelatin preparation method.
  • Injection preparation was prepared by dissolving active component, controlling pH to about 7.5 and then filling all the components in 2ml ample and sterilizing by conventional injection preparation method.
  • Liquid preparation was prepared by dissolving active component, filling all the components and sterilizing by conventional liquid preparation method.
  • Vitamin mixture optimum amount
  • Health beverage preparation was prepared by dissolving active component, mixing, stirred at 85°C for 1 hour, filtered and then filling all the components in IOOOD ample and sterilizing by conventional health beverage preparation method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une préparation comprenant un extrait de Rubus coreanus Miquel, ou un extrait fermenté de Rubus coreanus Miquel, au titre de principe actif. Ladite préparation peut être employée dans le traitement prophylactique et thérapeutique des troubles sexuels causés par la diminution du taux de testostérone tels que les troubles de l'érection et les phénomènes anaphrodisiaques. L'extrait selon l'invention permet d'augmenter de façon significative le taux de testostérone et la population de cellules de Leydig qui produisent la testostérone, sans présenter de toxicité. L'extrait selon l'invention peut donc être employé en tant que médicament ou alicament dans le traitement prophylactique ou thérapeutique des troubles sexuels causés par la diminution du taux de testostérone.
PCT/KR2005/004456 2004-12-28 2005-12-22 Préparation comprenant un extrait de rubus coreanus miquel au titre de principe actif et stimulant la sécrétion de testostérone Ceased WO2006071024A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2004-0114316 2004-12-28
KR20040114316A KR100771987B1 (ko) 2004-12-28 2004-12-28 테스토스테론 분비 증강 효과를 갖는 복분자 추출물을유효 성분으로 함유한 조성물

Publications (1)

Publication Number Publication Date
WO2006071024A1 true WO2006071024A1 (fr) 2006-07-06

Family

ID=36615113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/004456 Ceased WO2006071024A1 (fr) 2004-12-28 2005-12-22 Préparation comprenant un extrait de rubus coreanus miquel au titre de principe actif et stimulant la sécrétion de testostérone

Country Status (2)

Country Link
KR (1) KR100771987B1 (fr)
WO (1) WO2006071024A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101043596B1 (ko) * 2008-07-29 2011-06-22 전라북도 고창군 복분자추출물을 이용한 비뇨기능 개선용 조성물

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000319191A (ja) * 1999-03-05 2000-11-21 Takeda Chem Ind Ltd サイクリックｇｍｐ特異的ホスホジエステラーゼ阻害剤および性的機能障害改善薬
KR100364684B1 (en) * 2002-09-04 2002-12-16 Korea Medical Science Inst Composition containing plant extract for promoting and maintaining erection
WO2003037246A2 (fr) * 2001-07-17 2003-05-08 Integrated Chinese Medicine Holdings Ltd. Compositions et methodes pour soins et contre les troubles prostatiques et hepatiques, preparation a base d'herbes medicinales
KR20030035482A (ko) * 2001-10-31 2003-05-09 주식회사 케이티앤지 성기능 개선용 홍삼복합물, 용도 및 그의 제조방법
KR20040034328A (ko) * 2003-03-12 2004-04-28 (주)바이오피아 성기능 장해 개선용 홍삼 복합물 조성 및 이를 함유하는식품
KR20040085295A (ko) * 2003-03-31 2004-10-08 선만규 유산균을 이용한 복분자 발효음료의 제조방법
KR20040092232A (ko) * 2003-04-25 2004-11-03 주식회사 케이티앤지 성기능 개선용 홍삼복합물, 이의 제조방법 및 이의 용도
KR100463130B1 (ko) * 2001-05-25 2004-12-23 한국식품연구원 남성 성기능 개선용 기능성 식품
KR20040108512A (ko) * 2003-06-17 2004-12-24 주식회사 닥터즈메디코아 혼합 생약재 추출물 및 이를 유효성분으로 함유하는발기부전 치료용 조성물
KR20060014685A (ko) * 2004-08-11 2006-02-16 최진호 복분자 추출물을 주재로한 발기촉진제와 그의 제조방법 및그의 강화보조식품

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001001025A (ja) * 1999-06-24 2001-01-09 Sumitomo Metal Ind Ltd 冷間圧延方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000319191A (ja) * 1999-03-05 2000-11-21 Takeda Chem Ind Ltd サイクリックｇｍｐ特異的ホスホジエステラーゼ阻害剤および性的機能障害改善薬
KR100463130B1 (ko) * 2001-05-25 2004-12-23 한국식품연구원 남성 성기능 개선용 기능성 식품
WO2003037246A2 (fr) * 2001-07-17 2003-05-08 Integrated Chinese Medicine Holdings Ltd. Compositions et methodes pour soins et contre les troubles prostatiques et hepatiques, preparation a base d'herbes medicinales
KR20030035482A (ko) * 2001-10-31 2003-05-09 주식회사 케이티앤지 성기능 개선용 홍삼복합물, 용도 및 그의 제조방법
KR100364684B1 (en) * 2002-09-04 2002-12-16 Korea Medical Science Inst Composition containing plant extract for promoting and maintaining erection
KR20040034328A (ko) * 2003-03-12 2004-04-28 (주)바이오피아 성기능 장해 개선용 홍삼 복합물 조성 및 이를 함유하는식품
KR20040085295A (ko) * 2003-03-31 2004-10-08 선만규 유산균을 이용한 복분자 발효음료의 제조방법
KR20040092232A (ko) * 2003-04-25 2004-11-03 주식회사 케이티앤지 성기능 개선용 홍삼복합물, 이의 제조방법 및 이의 용도
KR20040108512A (ko) * 2003-06-17 2004-12-24 주식회사 닥터즈메디코아 혼합 생약재 추출물 및 이를 유효성분으로 함유하는발기부전 치료용 조성물
KR20060014685A (ko) * 2004-08-11 2006-02-16 최진호 복분자 추출물을 주재로한 발기촉진제와 그의 제조방법 및그의 강화보조식품

Also Published As

Publication number Publication date
KR100771987B1 (ko) 2007-10-31
KR20060075516A (ko) 2006-07-04

Similar Documents

Publication Publication Date Title
US8084061B2 (en) Body fat-reducing agent
EP1505994B1 (fr) Nouvelle utilisation de l'extrait de ginseng traite et saponine isolee a partir de ce dernier
EP2436388B1 (fr) Composition pour accroître de la biodisponibilité de la saponine
US20100068315A1 (en) Composition Comprising an Extract of Gramineae Plant for the Prevention and Treatment of Ischemic Diseases and Degenerative Brain Diseases and the Use Thereof
EP3017821B1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
US20240245742A1 (en) Composition Comprising Elderberry Extract as Effective Component for Preventing, Treating, or Alleviating Andropause Syndrome
KR101054594B1 (ko) 간 기능 개선제 조성물
KR101552813B1 (ko) 사군자 추출물을 함유하는 전립선 비대증 예방 또는 치료용 조성물
EP3144005A1 (fr) Composition pour la prévention et le traitement de l'infertilité masculine, contenant un extrait d'herbes mixtes en tant qu'ingrédient actif et utilisation de celle-ci
WO2005044291A1 (fr) Extrait de pepin de raisin presentant une activite de protection des cellules neuronales et composition comprenant un tel extrait afin de prevenir et de traiter une maladie cerebrale degenerative
KR20160141027A (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품
KR102025572B1 (ko) 고욤나무 잎 및 포도송이 줄기 추출물의 혼합물을 유효성분으로 함유하는 대사성 질환의 예방, 개선 또는 치료용 조성물
WO2006071024A1 (fr) Préparation comprenant un extrait de rubus coreanus miquel au titre de principe actif et stimulant la sécrétion de testostérone
KR101795261B1 (ko) 구기자를 포함하는 간 기능 개선용 한방조성물 및 그 제조방법
AU2023250019A1 (en) Improving semen quality
KR20140036966A (ko) 제주조릿대 잎을 이용한 운동수행능력향상용 조성물 또는 피로회복용 조성물
KR20140080289A (ko) 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법
KR20110078237A (ko) 비파 추출물을 함유하는 비만 치료 또는 예방용 조성물
KR20180124426A (ko) 빅벨리해마 알칼레이즈 가수분해물을 이용한 근육 성장 또는 운동 능력 개선용 조성물
KR102408908B1 (ko) 복합 소재 추출물을 포함하는 비만의 예방 또는 개선용 건강기능식품
KR101908850B1 (ko) 구기자를 포함하는 항비만 한방조성물 및 그 제조방법
KR101735294B1 (ko) 산화적 뇌손상 및 뇌기능 장애의 예방 또는 치료용 조성물 및 이의 제조방법
CN111035017A (zh) 一种防治肌肉流失的口服液
KR20200096139A (ko) 숙취 해소용 조성물 및 그 제조방법
KR102149783B1 (ko) 미선나무 추출물을 유효성분으로 포함하는 간 손상 억제, 예방, 개선 또는 치료용 약학 조성물 및 건강기능식품

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05821946

Country of ref document: EP

Kind code of ref document: A1